文献速递血栓与止血

生长分化因子-15与癌症相关血栓形成及死亡风险的预测:一项前瞻性队列研究

Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
PubMed 文献 · J Thromb Haemost · 2023-05-14

维也纳癌症与血栓研究(CATS)前瞻性观察队列纳入1531例新诊断或复发癌症患者,随访2年,评估血清GDF-15与VTE、ATE及死亡的关系。GDF-15每翻倍与全因死亡独立相关(HR 1.21,95%CI 1.10-1.33),但与VTE、ATE的关联在校正后未持续,且未改善Khorana或Vienna CATScore的预测性能。

要点

  • GDF-15每翻倍与全因死亡独立相关,HR 1.21(95%CI 1.10-1.33)。
  • GDF-15每翻倍与VTE、ATE的关联在校正混杂后未持续。
  • GDF-15未改善Khorana或Vienna CATScore对VTE的预测性能。

核心结论

  • GDF-15与癌症患者生存强相关,且独立于已确立的危险因素。
  • 单变量分析中GDF-15与ATE和VTE存在关联,但校正后未独立相关,且未能改善已建立的VTE预测模型。

研究设计与样本

  • 维也纳癌症与血栓研究(CATS)是一项前瞻性观察性队列研究,纳入新诊断或复发癌症患者,随访2年。
  • 共纳入1531例癌症患者,中位年龄62岁,男性占53%。
  • 检测研究入组时血清GDF-15水平,采用竞争风险模型(VTE/ATE)或Cox回归(死亡)分析关联。
  • 采用Khorana和Vienna CATScore评估GDF-15对已建立VTE风险预测模型的附加价值。

主要发现

  • GDF-15中位水平为1004 ng/L(IQR 654-1750)。
  • GDF-15每翻倍与VTE风险升高相关,亚分布风险比1.16(95%CI 1.03-1.32)。
  • GDF-15每翻倍与ATE风险升高相关,亚分布风险比1.30(95%CI 1.11-1.53)。
  • GDF-15每翻倍与全因死亡风险升高相关,风险比1.57(95%CI 1.46-1.69)。
  • 校正临床相关协变量后,仅全因死亡关联持续存在,风险比1.21(95%CI 1.10-1.33);GDF-15未改善Khorana或Vienna CATScore的预测性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cancer are at increased risk of venous thromboembolism (VTE) and arterial thromboembolic/thrombotic events (ATEs). Growth differentiation factor-15 (GDF-15) improves cardiovascular risk assessment, but its predictive utility in patients with cancer remains undefined. OBJECTIVES: To investigate the association of GDF-15 with the risks of VTE, ATE, and mortality in patients with cancer and its predictive utility alongside established models. METHODS: The Vienna Cancer and Thrombosis Study (CATS)-a prospective, observational cohort study of patients with newly diagnosed or recurrent cancer-which was followed for 2 years, served as the study framework. Serum GDF-15 levels at study inclusion were measured, and any association with VTE, ATE, and death was determined using competing risk (VTE/ATE) or Cox regression (death) modeling. The added value of GDF-15 to established VTE risk prediction models was assessed using the Khorana and Vienna CATScore. RESULTS: Among 1531 included patients with cancer (median age, 62 years; 53% men), median GDF-15 levels were 1004 ng/L (IQR, 654-1750). Increasing levels of GDF-15 were associated with the increased risks of VTE, ATE, and all-cause death ([subdistribution] hazard ratio per doubling, 1.16 [95% CI, 1.03-1.32], 1.30 [95% CI, 1.11-1.53], and 1.57 [95% CI, 1.46-1.69], respectively). After adjustment for clinically relevant covariates, the association only prevailed for all-cause death (hazard ratio, 1.21; 95% CI, 1.10-1.33) and GDF-15 did not improve the performance of the Khorana or Vienna CATScore. CONCLUSION: GDF-15 is strongly associated with survival in patients with cancer, independent of the established risk factors. While an association with ATE and VTE was identified in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nopp S, Moik F, Kraler S, et al. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study. J Thromb Haemost. 2023. PMID: 37192696. doi:10.1016/j.jtha.2023.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。